Case Management - Regeneron Pharmaceuticals, Inc. and another v Rinat Neuroscience Corp.
Jane Lambert Patents Court (Mr Justice Birss) Regeneron Pharmaceuticals, Inc. and another v Rinat Neuroscience Corp . [2020] EWHC 3359 (Pat) (7 Dec 2020) Interest rei publicae ut sit finis litium. This pithy maxim is usually trotted out in res judicata cases but it can apply equally to a claim such as this. It might even apply to attempts to frustrate the outcome of the recent US presidential election. According to the transcript, the claimants are about to launch a treatment for osteoarthritis called fasinumab . They were prevented from doing so by three patents, namely: EP (UK) 2,270,048 , EP (UK) 2,305,711 , and EP (UK) 1,871,416. . The claimants applied for revocation of those patents to clear the way for the marketing of their treatment. Two points to note about the patents is that the second and third of those patents were divisionals of the first and that all three patents were for second medical uses of known medicament...